The use of laser therapy in urology against cancer, such as bladder and prostate, has been increasing because of its advantages of minimally invasiveness and high accuracy.1 However, the maldistribution of optical energy can lead to unintended stimulation of cancer cells.2 Therefore, this study aims to investigate the stimulative effects of wavelength-dependent biomodulation on prostate cancer. Human-derived prostate cancer cell line DU145 was exposed to four different laser wavelengths (405, 532, 635 and 808nm) at a dose of 10J/cm2. After the laser irradiation, cell viability and ERK protein expression were assessed by using MTT assay and Western blot. For in vivo tests, DU145 xenograft models were used, and the tumors were extracted for histological analysis after ten days of volume monitoring. Among the wavelengths, the 808nm laser consistently increased cell viability by up to 21% for 24, 48, and 72 hours after the irradiation, compared to the control. The ERK protein expression was promoted by the irradiation of 405 and 808nm laser light. The in vivo tests showed that the 808nm laser significantly increased relative tumor volume (V/V0) up to 150% while the control group increased V/V0 up to 45%. Immunohistochemistry (IHC) staining of the sectioned tumor represented that VEGF and HIF-1a expression were induced after the exposure to the 808nm laser light. The current findings showed that depending on the wavelength, low level laser irradiation may affect the proliferation of prostate cancer cells, stimulating the tumor growth in the tumor microenvironment.
|